4.6 Review

The chemical tool-kit for molecular imaging with radionuclides in the age of targeted and immune therapy

Journal

CANCER IMAGING
Volume 21, Issue 1, Pages -

Publisher

BMC
DOI: 10.1186/s40644-021-00385-8

Keywords

PET; SPECT; Molecular imaging; Radiochemistry; Radiopharmaceuticals; Total body PET; Radionuclides

Funding

  1. Wellcome Trust
  2. EPSRC [EP/S032789/1]
  3. EPSRC [EP/S032789/1] Funding Source: UKRI

Ask authors/readers for more resources

Nuclear medicine has evolved over the past half-century from a functional imaging modality to a modern specialty known as molecular imaging, with a wide range of specific radioactive probes with known structures. Advances in cancer treatment towards targeted therapies and the recognition of cancer cell phenotype heterogeneity have led to a growing need for personalized molecular imaging.
Nuclear medicine has evolved over the last half-century from a functional imaging modality using a handful of radiopharmaceuticals, many of unknown structure and mechanism of action, into a modern speciality that can properly be described as molecular imaging, with a very large number of specific radioactive probes of known structure that image specific molecular processes. The advances of cancer treatment in recent decades towards targeted and immune therapies, combined with recognition of heterogeneity of cancer cell phenotype among patients, within patients and even within tumours, has created a growing need for personalised molecular imaging to support treatment decision. This article describes the evolution of the present vast range of radioactive probes - radiopharmaceuticals - leveraging a wide variety of chemical disciplines, over the last half century. These radiochemical innovations have been inspired by the need to support personalised medicine and also by the parallel development in development of new radionuclide imaging technologies - from gamma scintigraphy, through single photon emission tomography (SPECT), through the rise of clinical positron emission tomography (PET) and PET-CT, and perhaps in the future, by the advent of total body PET. Thus, in the interdisciplinary world of nuclear medicine and molecular imaging, as quickly as radiochemistry solutions are developed to meet new needs in cancer imaging, new challenges emerge as developments in one contributing technology drive innovations in the others.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available